Company: EVGN
Filing Date: 2025-09-30
Form Type: POS AM
Source: 0001178913-25-003429
Chunk: 13

Company: Evogene Ltd.
Filing Date: 2025-09-30
Form: POS AM
Chunk 13
---
 changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. 8 USE OF PROCEEDS We will not receive any proceeds from the sale of the ordinary shares by the Selling Shareholder. We will, however, receive up to an aggregate of approximately $12.02 million in cash from the exercise of the ordinary warrants, assuming the exercise in full of all the warrants, which we intend to use for research and development, working capital, investments in our subsidiaries, sales and marketing activities and for general corporate purposes. We may also use a portion of the net of proceeds from the exercise of any warrants by the Selling Shareholder to acquire or invest in technologies, products and/or businesses that we believe are complementary to ours. The Selling Shareholder will receive all of the net proceeds from the sale of any ordinary shares offered by it under this prospectus. See “Selling Shareholder”. The Selling Shareholder will pay any underwriting discounts and commissions and expenses incurred by the Selling Shareholder for brokerage, accounting, tax, legal services or any other expenses incurred by the Selling Shareholder in disposing of these ordinary shares. We will bear all other costs, fees and expenses incurred in effecting the registration of the sale of the ordinary shares covered by this prospectus. 9 CAPITALIZATION The following table sets forth our cash and cash equivalents and capitalization as of June 30, 2025:

| • | on an actual basis; and                                                                                                                                                                       |
| • | on a pro-forma basis to give effect to the issuance of an additional 3,384,616 ordinary shares issuable upon exercise of the ordinary warrants that were issued in the private placement that 
 was completed on August 26, 2024.                                                                                                                                                             |

|                                                            |     | As of June 30, 2025         |          |   |     |           |          |   |
|:-----------------------------------------------------------|:----|:----------------------------|---------:|:--|:----|:----------|---------:|:--|
|                                                            |     | Actual                      |          |   |     | Pro forma |          |   |
|                                                            |     | -unaudited                  |          |   |     |           |          |   |
|                                                            |     | -U.S. Dollars, in thousands |          |   |     |           |          |